Objectives: The effects (16 weeks) of oral antihypertensive drugs on right atrial (RA) function were evaluated by two-dimensional and Doppler echocardiography in 64 patients with mild-to-moderate essential hypertension. Thirty-two age-and sex-matched normal subjects served as controls. Background: Hypertension alters the diastolic properties of the left ventricle and disturbs the left atrial contractile activities. RA performance may also alter in essential hypertension. Methods: From the tricuspid flow velocity curves the E/A ratio, the velocity-time integrals (Ei and Ai, respectively) as well as the sum, TTi ‫؍‬ Ei ؉ Ai, were measured. RA active contribution (RAAC) was expressed as the ratio RAAC ‫؍‬ Ai/TTi. Results: RA-A/E ratio, RA-Ai and RAAC were increased while RA-TTi were decreased in hypertensives compared to controls, P Ͻ 0.0001 for all comparisions. After
Introduction
Several reports indicated a direct relationship between arterial hypertension and left atrial dysfunction, [1] [2] [3] [4] [5] [6] but few studies have been reported investigating the right atrial (RA) performance in hypertensive patients. 7 In particular, the relationship between increase in blood pressure, left ventricular hypertrophy and RA function is still uncertain. Furthermore, an abnormal right ventricular (RV) relaxation may determine RA contribution to RV filling, whereas it is controversial whether RA dysfunction is a consequence of increased afterload itself or rather of changes in right or left ventricular structure or function that may occur in patients with arterial hypertension.
Systemic hypertension may be associated with elevation of pulmonary arterial pressure and of pulmonary arterial resistance which is not necessarily a consequence of impairment in left ventricular function. Left ventricular hypertrophy is associated with enhanced performance of either ventricle. In coincidence with development of severe left ventricular hypertrophy and diastolic dysfunction, the performance of both sides of the heart may deteriorate. 7 Under these circumstances the status of RA function is an important determinant of RV performance and haemodynamic compromise. 8 The RV and RA function has been assessed in experimental and clinical conditions. [7] [8] [9] [10] Noninvasive RA function has been performed with echocardiography by means of RA volume measurements. [11] [12] [13] Indirectly, RA function can also be evaluated with the use of pulsed Doppler echocardiography by means of trans-tricuspid flow velocity measurements in a similar manner with that used for the estimation of left atrial function. 14, 15 Two of the most commonly used groups of antihypertensive drugs in patients with essential hypertension are angiotensin-converting enzyme inhibitors and calcium-channel antagonists. The precise effects on RA function of various antihypertensive drugs are not totally clear. The present study was performed to evaluate the effects of systemic hypertension on RV and RA function. Therefore, a control group consisted of normotensive subjects without history of cardiovascular disease, was compared with age-matched hypertensive patients. Secondly, we examined the effects of ramipril, an angiotensinconverting enzyme inhibitor, and amlodipine, a calcium-channel antagonist, on RA function, in patients with mild-to-moderate hypertension.
Subjects and methods

Study population
Sixty-four patients (49 men and 15 women) with mild-to-moderate essential hypertension, were the subjects of this report. Their mean age was 48 Ϯ 12 (range 39 to 77) years. The patients had either never received antihypertensive therapy previously or had all antihypertensive medications discontinued at least 4 weeks before entry into the study. Clinical evaluation for secondary forms of hypertension had failed to demonstrate a primary cause of hypertension. Patients were included in the study only if their diastolic pressures were equal to or higher than 90 mm Hg and less than 120 mm Hg on at least two consecutive out-patient visits during the 2 weeks before antihypertensive therapy was instituted. Patients were excluded if they had significant valvular heart disease, congenital heart disease, and idiopathic cardiomyopathy, left ventricular ejection fraction Ͻ55%, chronic obstructive pulmonary disease, congestive heart failure, renal failure or any other systemic disease. Thirty-two normotensive patients without a history of cardiovascular disease served as controls.
Tricuspid and pulmonary flow velocity profiles were adequately visualised from the apical fourchamber and the basal short-axis view, respectively. These criteria were met in these 96 subjects after 102 subjects (34 controls and 68 patients) were initially screened. Thus, two control subjects and four hypertensive patients had to be rejected because of suboptimal echocardiograms. Informed written consent, previously approved by our institutional study committee, was obtained from the patients after they were provided with a detailed description of the protocol.
Echocardiographic assessment
Patients were studied in the echocardiographic laboratory after an overnight fast. Two-dimensional and Doppler echocardiograms were recorded before and after 16 weeks of oral antihypertensive therapy. Echocardiographic data were recorded on a HewlettPackard sonos 1500 echocardiograph equipped with a 2.5 MHz transducer. Two-dimensional echocardiographic images at the apical four chamber and the basal short-axis views as well as Doppler signals simultaneously with the electrocardiogram were obtained at a steady state.
Two-dimensional study
A standard four-chamber view of the heart from the apical window was recorded. The transducer was carefully angled to qualitatively maximise RV and RA size and gain positions were adjusted to obtain the clearest outline of the endocardium. RV areas were obtained at end-diastole and end-systole (RVEDA and RVESA, respectively). RA measurements were obtained from two-dimensional echograms with the largest RA size at the end of ventricular systole. The area of the right ventricle and atrium was planed. Special attention was focused on tracings of chamber images. Thus, in the four-chamber apical view, if the ventricular or atrial septum partially dropped out their location were approximated by reconstructing their image from visualised fragments. Moreover, instead of tracing along the inner surface of the coapted tricuspid valve, a straight line connecting both sides of the leaflet base attachment points to the valve ring was taken as the border between ventricle and atrium. Both the atrial appendage and the inferior vena cava, when visualised were carefully excluded. 16 The RV stroke area was calculated as RVEDA-RVESA, and RV fractional area change as RV-FAC ϭ (RVEDA-RVESA)/RVEDA. RV-FAC was used as a systolic index of RV ejection phase. 17 Left ventricular posterior and septal wall thickness and systolic and diastolic dimensions were measured using five consecutive cycles. Enddiastole was taken at the R-wave, and end systole, at the smallest internal dimension. Left ventricular views at the high chordal level were selected. Left ventricular mass was calculated according to the Penn convention. 
Doppler flow velocity analysis
Pulsed-wave Doppler measurements were obtained by placing the sample volume at the tip of the tricuspid valve leaflets to obtain the highest velocity. Colour flow imaging was used to obtain a beam direction as parallel as possible to tricuspid flow. The tricuspid flow velocity profiles were traced directly by hand along the instantaneous highest velocity spectra ( Figure 1 ). Five consecutive tricuspid flow velocity curves were analysed for the derivation of the following variables: the peak flow velocity of RV early and late diastolic filling (E and A waves); the E/A ratio; and the velocity-time integrals of early and late Doppler velocities (Ei and Ai, respectively). In tracings in which E and A waves were not completely separate, the descending limb of the E wave was extrapolated to the baseline to define the Ewave flow-velocity integral, and the remainder of the tracing was considered as the A wave. RA active contribution (RAAC) was expressed as the ratio of the atrial component during active atrial contraction (Ai) to the total diastolic time velocity integral (TTi ϭ Ei ϩ Ai), calculated as [RAAC ϭ Ai/TTi]. 14, 15, 18 The RV outflow tract was obtained from the standard short axis view at the base of the heart, with the transducer in the parasternal position. The pulmonary valve and the pulmonary artery were recorded with slight variation in angulation of the transducer. Pulsed-wave Doppler measurements were obtained by placing the sample volume at the tip of the pulmonary valve leaflets to obtain the highest velocity. Colour flow imaging was used to obtain a beam direction as parallel as possible to pulmonary blood flow. The time from the beginning of the QRS to the leading edge of the pulmonary closure artifact seen on pulsed wave Doppler pulmonary artery velocity, and the time from the beginning of the QRS to the onset of the trans-tricuspid blood flow, were measured. RV isovolumetric relaxation time (RV-IVRT) was calculated as the difference between these time intervals, expressing the rate of RV relaxation. 14 
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Recordings were made at steady state during endexpiration apnea holding the position of the transducer on the thoracic wall as constant as possible during the entire procedure. The author was unaware of the measurements of the first echocardiogram when performing the second one after treatment. Furthermore, the author during the analysis of the echocardiographic data was kept blinded to all the clinical data including the kind of the antihypertensive treatment that was applied to each patient. The mean percentage values of intraobserver variability regarding the measurements of Ei, Ai, RV-IVRT, RV and RA areas were 6.8%, 7.3%, 5.2%, 7.9% and 8.0%, respectively.
Active treatment period
The first stage consisted of a randomised, parallel dosing, with 32 patients assigned to either ramipril or amlodipine. All patients met the blood pressure inclusion criteria and were started on drug therapy for 16 weeks and then evaluated again by the same echocardiographic methods. The initial amlodipine dose was 5 mg once a day or ramipril 2.5 mg once a day. The dosage was increased to 10 mg of amlodipine and 10 mg of ramipril during the third and fourth weeks if the dosage was considered inadequate to control the patient's blood pressure, respectively. Adequate control of blood pressure was defined as a fall in resting supine diastolic pressure to below 90 mm Hg or a reduction of 10 mm Hg or more for those patients whose pretreatment diastolic pressures were at least 90 but 100 or less mm Hg. Blood pressures were taken 12 h postdose.
Statistical analysis
Differences between control subjects and hypertensive patients were compared by independentsamples t-test (Table 1) . Qualitative data were compared with the use of the chi-square test. Prediction of RAAC, in the whole population at baseline was obtained by stepwise forward multiple linear regression analysis. Simple linear regression analysis was used to look at the extent of the fall in left ventricular mass against the improvement in diastolic function. Paired-samples t-test was used to compare baseline to effects of ramipril and amlodipine. Repeated measures analysis of variance (RMANOVA) was used to find out the significance of the differential effects of the drugs on the variables. Using General Linear Model procedure, we tested null hypotheses about the effects of the clinical and echocardiographic variables on the means of groups of RAAC, which was considered as the dependent variable. We investigated interactions between factors as well as the effects of individual factors (SPSS 8.0 for Windows). In addition, the effects of covariates and covariate interactions with factors were included. Statistical significance was defined as P Ͻ 0.05. The statistical power ranged from 85 to 100% to detect the changes in the various variables of the study.
Results
Of the 64 patients, all return to undergo echocardiographic evaluation after 16 weeks of antihypertensive therapy. Important side effects were not observed either during ramipril or during amlodipine therapy. Table 1 summarises the demographic data as well as the baseline haemodynamic and echocardiographic variables in control subjects and hypertensive patients. There were no differences in demographic data, left ventricular dimensions, ejection fraction, heart rate, RA dimension, RA Ei as well as in RV dimensions and fractional area change, at baseline between control subjects and hypertensive patients (P ϭ NS). All other haemodynamic and echocardiographic indices were significantly different between control subjects and hypertensive patients (P ϭ 0.000). With respect to RA function we found increased A/E ratio and RAAC while the RA Ei and RA total trans-tricuspid flow velocity integral was decreased in patients with hypertension compared to controls, P ϭ 0.000. Furthermore, RV-IVRT was significantly prolonged in arterial hypertension, P ϭ 0.000.
Effects of arterial hypertension on right atrial function
Effects of antihypertensive therapy
During the active treatment period, based on resting supine diastolic blood pressure, the dose of ramipril was doubled in 18 and was increased to 10 mg in eight out of 32 patients. The dose of amlodipine was doubled in 28 out of 32 patients. Effects on haemodynamic variables and cardiac function are shown in Table 2 . After 16 weeks of treatment supine systolic and diastolic blood pressure decreased by 18% and 20% in both groups, respectively (P ϭ 0.000). Left ventricular diameter, mass and ejection fraction changed significantly (P ϭ 0.000) with treatment. The decrease in left ventricular mass was greater with ramipril, P ϭ 0.000 (Table 2 , last column). Thirty-one patients of the ramipril group (97%) and 24 patients (75%) of the amlodipine group showed regression of left ventricular hypertrophy with a mean 12.1% (ramipril) and 10.8% (amlodipine) reduction in left ventricular mass, respectively. However, RV dimensions and ejection fraction index did not change, P ϭ NS. In contrast, RV-IVRT decreased in both groups (P ϭ 0.000) with greater reduction observed in the ramipril group (P ϭ 0.000). All RA functional indexes were normalised after treatment of hypertension, whereas the influences of the ramipril were enhanced compared to amlodipine, P ϭ 0.000 (Table 2 , last column). Figure 2 shows the data of RAAC on an individual basis.
Determinants of right atrial function
Stepwise multiple linear regression analysis for the pooled population (96 subjects) was performed at baseline data, expressing the RAAC as a function of age, sex, body surface area, left ventricular end-diastolic diameter, mass, and ejection fraction, RV enddiastolic and end-systolic area, and fractional area change, RV-IVRT, heart rate, systolic, diastolic and mean blood pressure, left atrial diameter, and A/E ratio, and RA area. Age (standardised coefficient 2.561, P ϭ 0.004), RV-IVRT (standardised coefficient 3.366, P Ͻ 0.001) and left ventricular mass (standardised coefficient 1.677, P Ͻ 0.001) were independent predictors of RAAC. The improvement in RV-IVRT was linearly correlated with the decrease in left ventricular mass in the patients, y ϭ 1.14 × −16.65, R 2 ϭ 0.60. Figure 2 Raw data of the right atrial contribution in controls and in hypertensive patients who received ramipril and amlodipine, before and after treatment.
The General Factorial procedure provides that left ventricular mass (P Ͻ 0.001) and RV-IVRT (P Ͻ 0.001) were significant effects and the interaction of category of drug (ramipril or amlodipine) with these two covariates was significant (P Ͻ 0.001). All the above-mentioned independent variables that were used in the stepwise multiple linear regression model were considered as covariates, apart from sex which was considered as factor.
Discussion
There are two principal findings in the present study. First systemic hypertension is associated with prolongation of RV relaxation rate
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accompanied with an increase in RA contribution to RV filling. A significant difference in both left and right atrial function was found in normotensive subjects compared to hypertensive patients. Second, these functional abnormalities are reversible with the proper antihypertensive therapy. The presence or absence of compensatory changes in RA function is important determinants of the hemodynamic impact of RV diastolic dysfunction.
Changes in right atrial function in hypertensive patients
This study confirmed the findings of previous ones with respect to alterations in left ventricular and left atrial structure and function, in patients with essential hypertension.
1-6 Indeed, not only left ventricular mass but also left atrial dimension and end-diastolic to first diastolic transmitral flow velocity ratios were increased. It has been reported that these changes are attributed to increased left ventricular afterload due to increased peripheral vascular resistance and elevation of left ventricular end-diastolic pressure. 19 An additional finding of the present study was the prolongation of RV relaxation rate while RV enddiastolic and end-systolic dimensions and ejection fraction did not differ significantly from normals. RV diastolic dysfunction was indicated by the prolonged RV-IVRT reflecting the effects of intrinsic RV myocardial stiffness. 8 The diastolic abnormality described should not be unexpected. Hypertension increases left ventricular intrinsic myocardial stiffness. 20 Diastolic coupling between the two ventricles and ventricular interdependence may lead to RV diastolic dysfunction. This effect appears to be mediated in part by shared encircling muscle bands and by the hypertrophied interventricular septum. 21 Furthermore, RA area tended to increase but did not reach a significant level. In contrast, all RA functional indices displayed significant alterations. Namely, RA contraction became vigorous as indicated by the increased A/E ratio and RAAC. On the other hand early filling as well as total trans-tricuspid RV filling was depressed. Increased RA contribution would be the expected response to increases in RA preload and afterload imposed by the stiff right ventricle. This response constitutes an important hemodynamic compensatory mechanism. 8, 9 Many factors are involved in these changes in hypertensives. First, an increased pulmonary arteriolar resistance should be involved which is of mechanical or vasomotor origin. [7] [8] [9] Increased afterload may also explain the impaired RV relaxation and the increased 'RA kick'. Based on the relationship that exists between left atrial and RA function an alternative explanation might be a common mechanism that produces vasoconstriction in the systemic and pulmonary circulation. This mechanism should probably be of neurohormonal origin. 7 Besides a functional interdependence of the two sides of the heart was previously documented in animal and in clinical studies. 21 We found that RAAC was independently associated with age, left ventricular mass and RV relaxation. These predictors are analogous to those of left atrial active contribution. Thus, a chronic increase of left ventricular afterload may have important effects on the whole heart, and again proposes the concept that the right and left sides of the heart represent a single functional unit. Because left ventricular mass is a common predictor to left and right atrial performance the same anatomical framework can be regarded as a reasonable mechanism of interdependence of the left and right heart. 7, 21, 22 
Effects of antihypertensive treatment
With the successful treatment of arterial hypertension, resulting in a significant reduction of left ventricular mass and RV relaxation time, RA performance was normalised. Thus, abnormal diastolic properties of left and right ventricles are improved by lowering arterial blood pressure and decreasing ventricular afterload. Both drugs ramipril and amlodipine, decreased mean arterial pressure and improved right and left ventricular diastolic filling patterns, by means of systemic and pulmonary vasodilatory actions. This normalisation should be explained not only by the improvement in left and RV diastolic function but also by another adaptive alteration in the RA function. In hypertensive patients RA function is more vigorous than in controls. This could be the result of an increase in plasma catecholamines and angiotensin-II. Thus, reduction of neurohormonal activation after treatment especially with ramipril may to some extent results in the decrease of atrial active contribution. This may be one of the mechanisms explaining the difference between amlodipine and ramipril in the degree of alterations that were observed in RA function indexes. 23 Indeed, changes in RA function indexes toward normal were greater in the ramipril group, as indicated by the significance level in the last column, of Table 2 . Another mechanism leading to this difference in the effects of drugs may be the specific modification of angiotensin from the angiotensin-converting enzyme inhibition in human atrial tissue. 24 Animal studies also suggested that angiotensin-converting enzyme inhibition improved haemodynamic parameters and decreased left and RV weight in hypertensive rats. Moreover, angiotensin-II causes pulmonary vasoconstriction in man and in animals, and angiotensin-converting enzyme inhibition has prevented the development of chronic pulmonary hypertension in animal models. 25 In contrast, calcium channels blockade in pulmonary hypertension causes adverse haemodynamic and clinical effects, including right heart failure during long-term treatment. 26 These deleterious responses are likely the result of a direct depressant effect exerted by calcium channel blockers on RV function independent of their pulmonary vasodilatory actions. 27 Furthermore, calcium channels blockers but not angiotensin-converting enzyme inhibitors, cause deterioration in pulmonary gas exchange. 28 An interesting finding of this study is the effects of left ventricular mass and RV-IVRT on the changes of RA performance induced by antihypertensive treatment as well as the significant interaction between these covariates and the treatment effect. This modification is an additional support of diastolic ventricular interaction, as changes in left ventricular mass and RV relaxation affect atrial active contribution. Changes in the abnormal diastolic orientation of the interventricular septum seen in our patients also reflect altered RV diastolic properties. Abnormal RA function was correlated with the septum hypertrophy and was reversed after treatment. Thus, the septum may in part mediate as well as reflect right heart dysfunction. 8, 9 Methodological considerations Two-dimensional and especially Doppler echocardiography is being used for the indirect evaluation of left ventricular diastolic function as well as left atrial performance. Previous studies have shown that the ratio of peak early to late diastolic mitral flow velocity, and left ventricular isovolumetric relaxation time are related to left ventricular haemodynamics and are influenced by age, loading conditions and other factors. 14, 15 Furthermore, it has been suggested that left atrial size and Doppler vari-ables have an additive value in estimating filling pressures of the left side of the heart. [4] [5] [6] In an effort to assess non-invasively RV and RA function we used indexes derived from two-dimensional and Doppler echocardiography similar to those used in the left side of the heart. 29, 30 The estimation of right chambers dimensions by any method makes geometric assumptions that have not extensively validated. The area was chosen in this study because it has been used in patients with variable RA and RV size.
11
Doppler flow velocity measurements were performed from a position providing the highest overall velocities, implying the least angulation with flow. Averaging consecutive cardiac cycles and measuring during end-expiration apnea has counterbalanced the effect of respiration on right-side flow. However, the tricuspid flow velocity pattern is also affected by many other factors such as RA function, RV systolic function and RV minimum pressure. 29, 30 Thus, RA function was only indirectly investigated.
RV isovolumetric relaxation time is measured by Doppler echocardiography in a manner analogous to left side dynamics and has helped improve the prediction of RA performance. In contrast to the left ventricle, however, measurement of RV-IVRT requires tricuspid and pulmonary flow velocity measurements at different times, which adds to the complexity of the evaluation. Moreover, the changes in systolic duration may not be associated with changes in ventricular relaxation rate and therefore measurements of IVRT both in left and right ventricle may be doubtful if not first corrected with often substantial, shifts in the timing of ventricular relaxation. 31 However, our findings of increased RV-IVRT in hypertension and the normalisation after treatment indicate that RV relaxation was impaired in arterial hypertension irrespective of the underlying physiological and pathophysiological concepts of the ventricular relaxation.
Haemodynamic and pressure data were not available in this study because the invasive measurements required in these patients, were felt to be ethically unjustified. Therefore, we did not have any values for invasive parameters such as the RV and RA pressures. Thus, the effects of drugs on RA function could not be fully investigated.
Clinical implications
Despite certain limitations, the results of this study suggest that tricuspid inflow, pulmonary flow and RA variables have additive value in the management of hypertensive patients. In these patients prolonged RV-IVRT and increased late to early trans-tricuspid peak velocity ratio indicate impaired RV relaxation and RA function. Conversely, a decrease in this ratio and in the RV-IVRT after treatment, indicate normalization of the performance of the right-side of the heart. Our results demonstrating normalisation of RA function and RV relaxation by the treatment of Journal of Human Hypertension hypertension and the regression of left ventricular hypertrophy offers another explanation for the beneficial effects of regressing ventricular hypertrophy and treating hypertensive heart failure. Whether the differential effects of ramipril and amlodipine are of clinical importance will require further study.
